title: Effect of mosapride on prednisolone-induced gastric mucosal injury and gastric-emptying disorder in dog.
abstract: Previous report demonstrated that prokinetic agent mosapride has anti-ulcerogenic action in rat-indomethacin gastric mucosal injury model. Here, we assessed the prophylactic effect of mosapride on gastric mucosal injury and emptying disorder induced by prednisolone in dogs. Crossover study design was employed. Six healthy beagles were administered prednisolone alone (2 mg/kg, twice a day [BID] subcutaneously) and prednisolone with mosapride (1 mg/kg, BID, orally), followed by an interval of at least 6 weeks. In each treatment, gastric mucosal injury was scored endoscopically according to the modified Lanza scale, and gastric emptying was assessed with (13)C-octanoic acid breath test. The incidence of gastrointestinal adverse events was also investigated. Coadministration of mosapride with prednisolone significantly (P<0.05) reduced the gastric mucosal injury score (mean ± SD, 17.67 ± 6.96), compared with that of prednisolone treatment alone (25.50 ± 13.03). Prednisolone treatment delayed the half-emptying time (184 ± 45 min) compared with that of controls (137 ± 19 min), and coadministration of mosapride improved this gastric-emptying delay (143 ± 29 min). Furthermore, the incidence of the gastrointestinal adverse event vomiting became less frequent upon coadministration with mosapride. In addition to its prokinetic action, our study suggests that mosapride has an anti-ulcerogenic action in dogs. The use of mosapride in combination with prednisolone is effective for attenuating prednisolone-induced gastrointestinal adverse events.
authors.affiliation: Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tsukamoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohno
authors.forename: Shingo
authors.initials: S
authors.lastname: Maeda
authors.forename: Ko
authors.initials: K
authors.lastname: Nakashima
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Fukushima
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Fujino
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Hori
authors.forename: Hajime
authors.initials: H
authors.lastname: Tsujimoto
mesh_terms: D000818:Animals; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use; D001944:Breath Tests; D002210:Caprylates / Q000378:metabolism; D002247:Carbon Isotopes / Q000378:metabolism; D018592:Cross-Over Studies; D017931:DNA Primers / Q000235:genetics; D004283:Dog Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology*; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D011239:Prednisolone / Q000009:adverse effects*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013272:Stomach Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary*; D013997:Time Factors
chemical_list: D001549:Benzamides; D002210:Caprylates; D002247:Carbon Isotopes; D017931:DNA Primers; D005765:Gastrointestinal Agents; D009025:Morpholines; D011239:Prednisolone; C062720:mosapride; C031492:octanoic acid